Olmesartan Enteropathy
Journal: International Journal of Celiac Disease (Vol.4, No. 1)Publication Date: 2016-03-17
Authors : Hugh James Freeman;
Page : 24-26
Keywords : celiac disease; sprue-like intestinal disease; drug-induced enteropathy; refractory celiac disease; collagenous sprue;
Abstract
Celiac disease is an immune-mediated small intestinal mucosal disorder with characteristic, but non-specific histopathological changes. A number of heterogeneous disorders may produce similar changes in small bowel biopsies, but these fail to respond to a gluten-free diet. Recently, it has become increasingly appreciated that different medications may cause this sprue-like intestinal disease, including a specific angiotensin II receptor antagonist, olmesartan, an agent often used for treatment of hypertension. This enteropathy appears to occur as an apparently rare adverse event, often presenting with severe diarrhea, malabsorption and weight loss following chronic long-term use of the drug. Serological studies, particularly for tissue transglutaminase IgA antibodies, are negative and biopsies may show moderate to severe changes in mucosal architecture similar to celiac disease. Sub-epithelial collagen deposits may also occur. Clinical and biopsy changes fail to respond to a strict gluten-free diet, but cessation of olmesartan use appears to result in resolution.
Other Latest Articles
- Gut-bone Cross Talks and Implications in Celiac Disease
- The Diagnosis of Patients with Celiac Disease and Calcium Deficiency
- Degree of Mucosal Damage and Clinical Presentation of Celiac Disease ? Is There a Connection?
- Is HLA Typing a Diagnostic Tool in Celiac Disease?
- Counting Intraepithelial Lymphocytes. Immunohistochemistry and Flow Cytometer are Necessary New Steps in the Diagnosis of Celiac Disease
Last modified: 2016-03-19 03:03:44